<DOC>
	<DOCNO>NCT02612428</DOCNO>
	<brief_summary>The primary objective study evaluate safety efficacy ELAD respect overall survival subject clinical diagnosis alcohol-induced liver decompensation ( AILD ) least Study Day 91 . The secondary objective evaluate proportion survivor Study Day 91 use chi-squared test .</brief_summary>
	<brief_title>Randomized , Open-Label , Multicenter , Controlled , Pivotal Study Assess Safety Efficacy ELAD Subjects w/ AILD</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis , Alcoholic</mesh_term>
	<criteria>Subjects must meet ALL inclusion criterion eligible study : 1 . Age ≥18 ; 2 . Total bilirubin ≥16 mg/dL ( ≥273.6 µmol/L ) ; 3 . A clinical diagnosis alcoholinduced liver decompensation ( AILD ) , base upon lab test medical history family interview causal relationship temporal association ( 6 week less ) alcohol use hospital admission episode AILD ; 4 . Maddrey score ≥32 ; 5 . Subjects must AILD severe acute alcoholic hepatitis ( sAAH ) diagnose either : . A confirmatory liver biopsy , OR b . Two follow : i. Hepatomegaly , ii . AST &gt; ALT , iii . Ascites , iv . Leukocytosis ( WBC count lab normal site ) ; Note : Subjects classify either : 1 . AILD sAAH underlie liver disease alcoholic liver disease , OR 2 . AILD sAAH evidence underlie liver disease alcoholic liver disease must document : i. Liver biopsy , AND/OR ii . Laboratory finding , AND/OR iii . Medical history ; 6 . Not eligible liver transplant hospitalization ; 7 . Subject legallyauthorized representative must provide Informed Consent ; 8 . Subject must eligible Standard Care treatment define protocol . Subjects must NOT exclusion criterion eligible study : 1 . Age ≥50 ; 2 . Platelet count &lt; 40,000/mm3 ; 3. International Normalization Ratio ( INR ) &gt; 2.5 ; 4 . Serum Creatinine ≥1.3 mg/dL ( ≥115.04 µmol/L ) ; 5 . MELD score ≥30 ; 6 . AST &gt; 500 IU/L ; 7 . Evidence infection unresponsive antibiotic ( e.g . increase tissue involvement relative initial diagnosis , clinical worsening symptom , etc . ) indicate follow : 1 . Presence sepsis septic shock ; OR 2 . Positive blood culture ( bacteremia , fungemia ) within 72 hour prior Randomization ; OR 3 . Presence spontaneous bacterial peritonitis 2 day prior Randomization ; OR 4 . Clinical radiological sign pneumonia ; 8 . Evidence reduction total bilirubin 20 % previous 72 hour . Bilirubin measurement must take least 12 hour procedure know artificially alter serum bilirubin ( e.g. , administration pack red blood cell , plasma exchange ) ; 9 . Evidence hemodynamic instability define follow : 1 . Systolic blood pressure &lt; 90 mmHg evidence diminish perfusion unresponsive fluid resuscitation and/or lowdose pressor support ; OR 2 . Mean arterial pressure ( MAP ) &lt; 60 mmHg evidence diminish perfusion unresponsive fluid resuscitation and/or lowdose pressor support ; OR 3 . Requirement escalate dos vasopressor support prior Screening ; OR 4 . Subject vasopressor , include limited list , dose follow Screening Randomization : Dobutamine : 5.0 µg/kg/min Dopamine : 2.0 µg/kg/min Norepinephrine : 0.02 µg/kg/min Phenylephrine : 1.0 µg/kg/min Vasopressin : 0.02 U/min 10 . Evidence active bleeding , major hemorrhage define require ≥2 unit pack red blood cell maintain stable hemoglobin occur within 48 hour prior Randomization , band gastroesophageal varix 7 day immediately precede screen ; 11 . Clinical evidence liver size reduction due cirrhosis [ liver size craniocaudal diameter ( sagittal view ) &lt; 10 cm measure mid clavicular line ( equivalent measurement ) ultrasound , liver volume &lt; 1200 cc determine CT MRI ] , unless Investigator interpretation clinical evidence indicate liver size &lt; 10 cm volume &lt; 1200 cc consider reduced individual subject , Sponsor agree ; 12 . Occlusive portal vein thrombosis impair hepatopetal flow , evidence bile duct obstruction ; 13 . Evidence physical exam , history , laboratory evaluation , significant concomitant disease life expectancy le 3 month , include , limited : 1 . Severe acute chronic cardiovascular , central nervous system , pulmonary disease ; 2 . Cancer metastasize yet treat ; 3 . Severe metabolic abnormality correct ( See Section 5.1.3 ) ; 14 . Subject chronic endstage renal disease require chronic hemodialysis 8 week ( classified hepatorenal syndrome ) ; 15 . Subject ventilate intubated ; 16 . Subject hemodialysis ; 17 . Subject liver disease relate homozygous hemachromotosis , Wilson 's disease , nonalcoholic fatty liver disease , BuddChiari Syndrome ; 18 . Serological evidence ( include viral titer ) active viral hepatitis A , B C infection . If investigator suspect subject may risk viral hepatitis A , B C , serology available , serology must obtain prior Randomization , positive serology would exclusionary ; 19 . Pregnancy determine serum βhuman chorionic gonadotropin ( HCG ) result , subject childbearing potential willing use effective mean contraception , without history medical surgical sterilization ; 20 . Participation another investigational drug , biologic , device study within one month enrollment , except observational study ( observational study set affect safety and/or efficacy VTL308 clinical trial ) ; 21 . Previous liver transplant ; 22 . Previous enrollment treatment phase another ELAD trial ; 23 . Have Do Not Resuscitate Do Not Intubate ( DNR/DNI ) directive ( local equivalent ) Advanced Directive limit Standard Care place ( DNR/DNI criterion applicable Europe ) ; 24 . Refusal participate VTL308E followup study ; 25 . Inability provide address home visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>